You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriflusal
Accession NumberDB08814
TypeSmall Molecule
GroupsApproved
DescriptionApproved by the European Stroke Organization, triflusal is recommended as lone therapy for the secondary prevention of atheroembotic stroke. Triflusal appears to be equally effective with a better safety profile than acetylsalicylic acid plus dypridamole and clopidogrel alone based on a double blind, randomized TACIP and TAPIRSS trials.
Structure
Thumb
Synonyms
Triflusal
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1Z0YFI05OO
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Taxonomy
ClassificationNot classified
Pharmacology
IndicationFor the pevention of cardiovascular events such as stroke, for acute treatment of cerebral infarction, myocardial infarction, and for thromboprophylaxis due to atrial fibrillation.
PharmacodynamicsTriflusal is an antithrombotic anticoagulant. It irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1. Triflusal affects many other targets such as NF kappa B, which is a gene expression regulatory factor for cycloxygenase-a and cytokines. Numerous studies comparing the efficacy and safety profile (i.e. systemic hemorrhage) between triflusal and acetylsalsylic acid has shown either no significant difference or a better effacy and safety profile for triflusal. Triflusal has been shown to protect cerebral tissue due to its inhibition of lipid peroxidation resulting from anoxia-reoxygenation.
Mechanism of actionTriflusal is chemically related to acetylsalicylic acid (ASA) and irreversibly inhibits cycloxygenase-1 (COX-1) in platelets. Acetylation of the active group of COX-1 prevents the formation of thromboxane-B2 in platelets. However, it is unique because it spares the arachidonic acid metabolic pathway in endothelial cells. In addition, it favors the production of nitric oxide, a vasodilator.
Related Articles
AbsorptionAbsorbed in the small intestine with a bioavailability range from 83% to 100%. There is no significant difference between the absorption of the oral solution and capsule formulation.
Volume of distribution

34L

Protein bindingBinds to plasma proteins almost entirely (99%)
Metabolism

In the liver, triflusal undergoes deacetylation, forming its main metabolite 2-OH-4-trifluoromethyl benzoic acid (HTB).

SubstrateEnzymesProduct
Triflusal
Not Available
2-hydroxy-4-trifluoromethyl benzoic acidDetails
Route of eliminationPrimarily renal.
Half lifeIn healthy human, the half life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.
Clearance

Renal clearance is 0.8 +/- 0.2L/h and 0.18 +/1 0.04L/h for triflusal and HTB, respectively.

ToxicityExcessive bleeding. The risk of bleeding is less than that of acetylsalicylic acid.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
References
Synthesis ReferenceNot Available
General References
  1. Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207. [PubMed:19465361 ]
  2. Izquierdo I, Borja J, Rovira S, Pelagio P, Torres F, Cebrecos J, Garcia-Rafanell J: Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study. Arzneimittelforschung. 2010;60(1):36-41. doi: 10.1055/s-0031-1296246. [PubMed:20184225 ]
  3. Duran X, Sanchez S, Vilahur G, Badimon L: Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2. J Thromb Haemost. 2008 Aug;6(8):1385-92. doi: 10.1111/j.1538-7836.2008.03036.x. Epub 2008 May 22. [PubMed:18503633 ]
  4. Quetglas EG, Campanero MA, Sadaba B, Escolar M, Azanza JR: Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers. Arzneimittelforschung. 2008;58(6):283-7. doi: 10.1055/s-0031-1296508. [PubMed:18677970 ]
  5. Gonzalez-Correa JA, De La Cruz JP: Triflusal: an antiplatelet drug with a neuroprotective effect? Cardiovasc Drug Rev. 2006 Spring;24(1):11-24. [PubMed:16939630 ]
  6. Fraj J, Valero A, Vives R, Perez I, Borja J, Izquierdo I, Picado C: Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases. Allergy. 2008 Jan;63(1):112-5. [PubMed:18053020 ]
  7. Sanchez-Machin I, Garcia Robaina JC, Torre Morin F: Widespread eczema from triflusal confirmed by patch testing. Contact Dermatitis. 2004 Apr;50(4):257. [PubMed:15186390 ]
  8. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, Melo T: Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke. 2003 Apr;34(4):840-8. Epub 2003 Mar 20. [PubMed:12649515 ]
  9. Culebras A, Rotta-Escalante R, Vila J, Dominguez R, Abiusi G, Famulari A, Rey R, Bauso-Tosselli L, Gori H, Ferrari J, Reich E: Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology. 2004 Apr 13;62(7):1073-80. [PubMed:15079004 ]
  10. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F: Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004296. [PubMed:16034926 ]
External Links
ATC CodesB01AC18
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabTriflusal may increase the anticoagulant activities of Abciximab.
AcenocoumarolTriflusal may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Triflusal.
AlprostadilAlprostadil may increase the anticoagulant activities of Triflusal.
AlprostadilTriflusal may increase the antiplatelet activities of Alprostadil.
AlteplaseTriflusal may increase the anticoagulant activities of Alteplase.
ALX-0081Triflusal may increase the anticoagulant activities of ALX-0081.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Triflusal.
AnagrelideAnagrelide may increase the anticoagulant activities of Triflusal.
AncrodTriflusal may increase the anticoagulant activities of Ancrod.
AnistreplaseTriflusal may increase the anticoagulant activities of Anistreplase.
Antithrombin III humanTriflusal may increase the anticoagulant activities of Antithrombin III human.
ApixabanTriflusal may increase the anticoagulant activities of Apixaban.
AprotininThe therapeutic efficacy of Triflusal can be decreased when used in combination with Aprotinin.
ArdeparinTriflusal may increase the anticoagulant activities of Ardeparin.
ArgatrobanTriflusal may increase the anticoagulant activities of Argatroban.
AstaxanthinTriflusal may increase the anticoagulant activities of Astaxanthin.
AzelastineAzelastine may increase the anticoagulant activities of Triflusal.
AzelastineTriflusal may increase the antiplatelet activities of Azelastine.
BatroxobinTriflusal may increase the anticoagulant activities of Batroxobin.
BecaplerminTriflusal may increase the anticoagulant activities of Becaplermin.
BemiparinTriflusal may increase the anticoagulant activities of Bemiparin.
BeraprostBeraprost may increase the anticoagulant activities of Triflusal.
BivalirudinTriflusal may increase the anticoagulant activities of Bivalirudin.
CangrelorCangrelor may increase the anticoagulant activities of Triflusal.
CertoparinTriflusal may increase the anticoagulant activities of Certoparin.
CilostazolCilostazol may increase the anticoagulant activities of Triflusal.
Citric AcidTriflusal may increase the anticoagulant activities of Citric Acid.
ClopidogrelClopidogrel may increase the anticoagulant activities of Triflusal.
CollagenaseThe risk or severity of adverse effects can be increased when Triflusal is combined with Collagenase.
Dabigatran etexilateTriflusal may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinTriflusal may increase the anticoagulant activities of Dalteparin.
DanaparoidTriflusal may increase the anticoagulant activities of Danaparoid.
DasatinibDasatinib may increase the anticoagulant activities of Triflusal.
DefibrotideDefibrotide may increase the anticoagulant activities of Triflusal.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Triflusal is combined with Deoxycholic Acid.
DesirudinTriflusal may increase the anticoagulant activities of Desirudin.
DesmoteplaseTriflusal may increase the anticoagulant activities of Desmoteplase.
DextranTriflusal may increase the anticoagulant activities of Dextran.
Dextran 40Triflusal may increase the anticoagulant activities of Dextran 40.
Dextran 70Triflusal may increase the anticoagulant activities of Dextran 70.
Dextran 75Triflusal may increase the anticoagulant activities of Dextran 75.
DicoumarolTriflusal may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Triflusal.
DipyridamoleDipyridamole may increase the anticoagulant activities of Triflusal.
DitazoleTriflusal may increase the anticoagulant activities of Ditazole.
Drotrecogin alfaTriflusal may increase the anticoagulant activities of Drotrecogin alfa.
Edetic AcidTriflusal may increase the anticoagulant activities of Edetic Acid.
EdoxabanTriflusal may increase the anticoagulant activities of Edoxaban.
EnoxaparinTriflusal may increase the anticoagulant activities of Enoxaparin.
EpinastineEpinastine may increase the anticoagulant activities of Triflusal.
EpinastineTriflusal may increase the antiplatelet activities of Epinastine.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Triflusal.
EptifibatideEptifibatide may increase the anticoagulant activities of Triflusal.
Ethyl biscoumacetateTriflusal may increase the anticoagulant activities of Ethyl biscoumacetate.
FibrinolysinTriflusal may increase the anticoagulant activities of Fibrinolysin.
Fondaparinux sodiumTriflusal may increase the anticoagulant activities of Fondaparinux sodium.
GlucosamineGlucosamine may increase the antiplatelet activities of Triflusal.
HeparinTriflusal may increase the anticoagulant activities of Heparin.
HirulogTriflusal may increase the anticoagulant activities of Hirulog.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Triflusal is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Triflusal.
IbudilastIbudilast may increase the anticoagulant activities of Triflusal.
IbudilastTriflusal may increase the antiplatelet activities of Ibudilast.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Triflusal.
Icosapent ethylTriflusal may increase the antiplatelet activities of Icosapent ethyl.
IfenprodilIfenprodil may increase the anticoagulant activities of Triflusal.
IfenprodilTriflusal may increase the antiplatelet activities of Ifenprodil.
IloprostIloprost may increase the anticoagulant activities of Triflusal.
LepirudinTriflusal may increase the anticoagulant activities of Lepirudin.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Triflusal.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Triflusal.
MilrinoneMilrinone may increase the anticoagulant activities of Triflusal.
MilrinoneTriflusal may increase the antiplatelet activities of Milrinone.
NadroparinTriflusal may increase the anticoagulant activities of Nadroparin.
NCX 4016NCX 4016 may increase the anticoagulant activities of Triflusal.
NimesulideNimesulide may increase the anticoagulant activities of Triflusal.
NimesulideTriflusal may increase the antiplatelet activities of Nimesulide.
ObinutuzumabThe risk or severity of adverse effects can be increased when Triflusal is combined with Obinutuzumab.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Triflusal.
OtamixabanTriflusal may increase the anticoagulant activities of Otamixaban.
ParnaparinTriflusal may increase the anticoagulant activities of Parnaparin.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Triflusal.
Pentosan PolysulfateTriflusal may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Triflusal.
PhenindioneTriflusal may increase the anticoagulant activities of Phenindione.
PhenprocoumonTriflusal may increase the anticoagulant activities of Phenprocoumon.
PlasminTriflusal may increase the anticoagulant activities of Plasmin.
PrasugrelPrasugrel may increase the anticoagulant activities of Triflusal.
Protein CTriflusal may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeTriflusal may increase the anticoagulant activities of Protocatechualdehyde.
ResveratrolResveratrol may increase the anticoagulant activities of Triflusal.
ResveratrolTriflusal may increase the antiplatelet activities of Resveratrol.
ReteplaseTriflusal may increase the anticoagulant activities of Reteplase.
ReviparinTriflusal may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Triflusal.
RidogrelTriflusal may increase the antiplatelet activities of Ridogrel.
RivaroxabanTriflusal may increase the anticoagulant activities of Rivaroxaban.
RosiglitazoneTriflusal may increase the anticoagulant activities of Rosiglitazone.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Triflusal.
SCH-530348SCH-530348 may increase the anticoagulant activities of Triflusal.
SCH-530348Triflusal may increase the antiplatelet activities of SCH-530348.
SelexipagTriflusal may increase the anticoagulant activities of Selexipag.
SevofluraneSevoflurane may increase the anticoagulant activities of Triflusal.
SevofluraneTriflusal may increase the antiplatelet activities of Sevoflurane.
SRT501SRT501 may increase the anticoagulant activities of Triflusal.
SRT501Triflusal may increase the antiplatelet activities of SRT501.
StreptokinaseTriflusal may increase the anticoagulant activities of Streptokinase.
SulodexideTriflusal may increase the anticoagulant activities of Sulodexide.
TenecteplaseTriflusal may increase the anticoagulant activities of Tenecteplase.
TesmilifeneTesmilifene may increase the anticoagulant activities of Triflusal.
TesmilifeneTriflusal may increase the antiplatelet activities of Tesmilifene.
TicagrelorTriflusal may increase the anticoagulant activities of Ticagrelor.
TiclopidineTiclopidine may increase the anticoagulant activities of Triflusal.
TinzaparinTriflusal may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the antiplatelet activities of Triflusal.
TirofibanTirofiban may increase the anticoagulant activities of Triflusal.
TositumomabThe risk or severity of adverse effects can be increased when Triflusal is combined with Tositumomab.
TranilastTranilast may increase the anticoagulant activities of Triflusal.
TranilastTriflusal may increase the antiplatelet activities of Tranilast.
TrapidilTrapidil may increase the anticoagulant activities of Triflusal.
TrapidilTriflusal may increase the antiplatelet activities of Trapidil.
TreprostinilTriflusal may increase the anticoagulant activities of Treprostinil.
TreprostinilTreprostinil may increase the antiplatelet activities of Triflusal.
UrokinaseTriflusal may increase the anticoagulant activities of Urokinase.
Vitamin EVitamin E may increase the antiplatelet activities of Triflusal.
VorapaxarTriflusal may increase the anticoagulant activities of Vorapaxar.
WarfarinTriflusal may increase the anticoagulant activities of Warfarin.
XimelagatranTriflusal may increase the anticoagulant activities of Ximelagatran.
Food Interactions
  • Gingko bilboa
  • Herbs with anticoagulant/antiplatelet activity such as alfalfa, feverfew, ginger, ginseng, grape seed, green tea, horseradish

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207. [PubMed:19465361 ]
  2. Dominguez MJ, Vacas M, Saez Y, Olabarria I, Velasco A, Iriarte JA, Forn J: Effects of triflusal in patients with prosthetic heart valves. Clin Ther. 1985;7(3):357-60. [PubMed:3838919 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Transcriptional repressor activity, rna polymerase ii transcription regulatory region sequence-specific binding
Specific Function:
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-co...
Gene Name:
NFKB1
Uniprot ID:
P19838
Molecular Weight:
105355.175 Da
References
  1. Zhang W, Potrovita I, Tarabin V, Herrmann O, Beer V, Weih F, Schneider A, Schwaninger M: Neuronal activation of NF-kappaB contributes to cell death in cerebral ischemia. J Cereb Blood Flow Metab. 2005 Jan;25(1):30-40. [PubMed:15678110 ]
  2. Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207. [PubMed:19465361 ]
  3. Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, Ferro JM, Gomez-Anson B, Manubens JM, Martinez-Lage JM, Munoz D, Pena-Casanova J, Torres F: A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):21-9. doi: 10.1097/WAD.0b013e3181611024. [PubMed:18317243 ]
  4. Whitehead SN, Bayona NA, Cheng G, Allen GV, Hachinski VC, Cechetto DF: Effects of triflusal and aspirin in a rat model of cerebral ischemia. Stroke. 2007 Feb;38(2):381-7. Epub 2006 Dec 28. [PubMed:17194886 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Tetrahydrobiopterin binding
Specific Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-n...
Gene Name:
NOS2
Uniprot ID:
P35228
Molecular Weight:
131116.3 Da
References
  1. Anninos H, Andrikopoulos G, Pastromas S, Sakellariou D, Theodorakis G, Vardas P: Triflusal: an old drug in modern antiplatelet therapy. Review of its action, use, safety and effectiveness. Hellenic J Cardiol. 2009 May-Jun;50(3):199-207. [PubMed:19465361 ]
  2. Sanchez de Miguel L, Casado S, Farre J, Garcia-Duran M, Rico LA, Monton M, Romero J, Bellver T, Sierra MP, Guerra JI, Mata P, Esteban A, Lopez-Farre A: Comparison of in vitro effects of triflusal and acetysalicylic acid on nitric oxide synthesis by human neutrophils. Eur J Pharmacol. 1998 Feb 5;343(1):57-65. [PubMed:9551715 ]
  3. De Miguel LS, Jimenez A, Monton M, Farre J, Del Mar Arriero M, Rodriguez-Feo JA, Garcia-Canete J, Rico L, Gomez J, Nunez A, Casado S, Farre AL: A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: role in platelet function. Eur J Clin Invest. 2000 Sep;30(9):811-7. [PubMed:10998082 ]
  4. Gonzalez-Correa JA, De La Cruz JP: Triflusal: an antiplatelet drug with a neuroprotective effect? Cardiovasc Drug Rev. 2006 Spring;24(1):11-24. [PubMed:16939630 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.
Gene Name:
PDE10A
Uniprot ID:
Q9Y233
Molecular Weight:
88411.71 Da
References
  1. McNeely W, Goa KL: Triflusal. Drugs. 1998 Jun;55(6):823-33; discussion 834-5. [PubMed:9617597 ]
  2. De Miguel LS, Jimenez A, Monton M, Farre J, Del Mar Arriero M, Rodriguez-Feo JA, Garcia-Canete J, Rico L, Gomez J, Nunez A, Casado S, Farre AL: A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: role in platelet function. Eur J Clin Invest. 2000 Sep;30(9):811-7. [PubMed:10998082 ]
Comments
comments powered by Disqus
Drug created on June 28, 2011 23:05 / Updated on August 17, 2016 12:24